NASDAQ:GMAB
Genmab ADR (GMAB)
Financials 
Technical Analysis 
Jun 2, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
Genmab (GMAB-Q), a biotech company based in Denmark, is receiving strong endorsements from experts following its recent earnings release. The company reported a remarkable 19% increase in revenues, significantly driven by a 54% surge in sales of its proprietary antibody treatments for cancer. Furthermore, the stock has been actively repurchased, bolstering cash reserves while retiring debt. Analysts project robust growth with an annual EPS growth rate that has exceeded 28% over the past five years and is expected to surpass 20% in the next five. With a current trading valuation that reflects a favorable earnings multiple and a solid return on equity, experts anticipate a strong upside potential for investors, maintaining a recommended stop-loss at $24 aiming for price targets ranging from $36.75 to $37.42.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentFollowing recently released earnings, we reiterate GMAB as a TOP PICK. The Danish based pharmaceutical company reported a 19% increase in revenues, thanks to a 54% increase in the sales of proprietary antibody treatments for cancer. Cash reserves grew while shares were aggressively bought back. It trades at 18x earnings, 3x book and supports a 17% ROE. We continue to recommend a stop at $24, looking to achieve $37 — upside potential of 32%. Yield 0%
(Analysts’ price target is $36.75)Premium contentGMAB is a biotech company based in the Netherlands producing human antibody treatments for cancer. It collects a royalty agreement with J&J that pays $14.3 billion, of which over half originates from the US and the balance from Europe. This is allowing for cash reserves to grow aggressively, while debt is retired. Annual EPS growth exceeds 28% over the past five years and analysts see growth over 20% over the next five. It trades at 16x earnings, 3.2x book and supports a 28% ROE. We recommend setting a stop-loss at $24, looking to achieve $37 -- upside potential of 23%. Yield 0%
(Analysts’ price target is $37.42)- «
- ‹
- 1
- ›
- »
Genmab ADR (GMAB) Frequently Asked Questions
What is Genmab ADR stock symbol?
Genmab ADR is a American stock, trading under the symbol GMAB (previously GMAB-Q on Stockchase) on the NASDAQ (GMAB). It is usually referred to as NASDAQ:GMAB or GMAB
Is Genmab ADR a buy or a sell?
In the last year, 1 stock analyst published opinions about GMAB (previously GMAB-Q on Stockchase). 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Genmab ADR.
Is Genmab ADR a good investment or a top pick?
Genmab ADR was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-02-12. Read the latest stock experts ratings for Genmab ADR.
Why is Genmab ADR stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
Is Genmab ADR worth watching?
In the last year, there was no coverage of Genmab ADR published on Stockchase.
What is Genmab ADR stock price?
On 2026-06-02, Genmab ADR (GMAB) stock closed at a price of $24.01.
Our PAST TOP PICK with GMAB has triggered its stop at $24. To remain disciplined, we recommend covering the position at this time. Combined with our previous guidance, this will result in a net investment loss of 17%.